Navigation Links
Zebra fish point the way towards new therapies for amyotrophic lateral sclerosis
Date:8/27/2012

Leuven scientists (VIB/KU Leuven) are using zebrafish as a model in their search for genes that play a role in the mechanism of amyotrophic lateral sclerosis (ALS). As a result, they have identified a molecule that could be the target for a future ALS treatment. ALS is a progressive degenerative motor neuron disease for which there currently is no treatment. Their study has been published in the prestigious journal Nature Medicine.

Amyotrophic lateral sclerosis or ALS

ALS is a progressive paralyzing disease caused by the destruction of the neurons connecting to the muscles. As a result, ALS patients gradually lose control over their muscles and eventually become completely paralyzed while their mental capacity remains intact. In spite of the enormous medical and social impacts of this grave degenerative illness, the mechanisms behind its pathogenesis remain a mystery. There is no known treatment.

Zebra fish as a model

Using an unusual zebrafish model for ALS that these scientists developed earlier, Wim Robberecht's research team searched for genes that either worsened or improved the phenotype of the disease. In the current study, Annelies Van Hoecke and Wim Robberecht and their colleagues identified the EphA4 receptor as a genetic factor that modifies the clinical picture of ALS in zebrafish. Eliminating this receptor in zebrafish led to the disappearance of the illness, while blocking the receptor in mice resulted in a clear improvement of the animals' life expectancy. The research also showed a link in ALS patients between the expression of the EphA4 receptor and the severity of the illness. ALS patients who express the receptor in limited amounts develop the disease later and have a better life expectancy than ALS patients who produce large amounts of the receptor. They also found that EphA4 prevented neurons from recovering from damage and that the cells that were actually the most susceptible to ALS expressed high levels of the receptor.

Proof-of-concept study

This study is very promising and proves that small model organisms such as zebrafish can be valuable tools in the search for a therapy for ALS. It also shows that molecules that are essential for the development of the nervous system can play a role in the mechanism of neurodegenerative disorders in adulthood. Finally, the results suggest that blocking EphA4 modifies the course of the disease, meaning that the receptor may be a good target for a future ALS drug. Of course, there is still a long road ahead before such a drug will be available to patients.


'/>"/>

Contact: Evy Vierstraete
info@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Study of zebra fish mouth formation may speak to Fraser syndrome hearing loss
2. Zebrafish -- the stars of biomedicine
3. Zebrafish provide insights into causes and treatment of human diseases
4. Zebrafish research shows how dietary fat regulates cholesterol absorption
5. Versatility of zebrafish research highlighted at international conference
6. Environmental estrogens affect early developmental activity in zebrafish
7. Zebrafish could hold the key to understanding psychiatric disorders
8. Better housing conditions for zebrafish could improve research results
9. U OF A expert pinpoints nutrient behind fresh water algae blooms
10. NPointer from Neurotechnology Uses Hand Gestures to Control and Navigate Computer Programs Without a Mouse or Touchpad
11. Chromosomal translocations point the way toward personalized cancer care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... 2016   Neurotechnology , a provider ... technologies, today released FingerCell 3.0, a software ... that run on low-power, low-memory microcontrollers. FingerCell ... than 128KB of memory, enabling it to ... limited on-board resources, such as: mobile phones, ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox ... response to client demand KbioBox developed a sophisticated “3 click” gene dditing off ... accessible from KBioBox’s new website, https://www.kbiobox.com/ and powered by the ...
(Date:12/8/2016)... ... ... This CAST literature review and report looks at problems caused by the current ... in countries that are major global commodity exporters and importers, which show that asynchrony ... level presence (LLP) puts large volumes of trade worth billions of dollars at risk. ...
(Date:12/8/2016)... TAMPA, Fla. , Dec. 8, 2016 /PRNewswire/ ... biopharmaceutical company that discovers, develops and plans to ... today that its shares of common stock were approved ... stock will begin trading on the OTCQX, effective ... To qualify for the OTCQX market, companies must ...
Breaking Biology Technology: